Therapeutic
plasma exchange (TPE) is a process in which plasma containing
antibodies,
immune complexes, inflammatory moderators,
paraproteins and other toxins which are believed to be the cause of disease is removed from a patient. TPE is the first-line treatment (category I, level 1A) in all forms of
Acute inflammatory demyelinating polyradiculoneuropathy disease (axonal, demyelinating and miller-fisher variant) as well as in acute myasthenic crisis,
chronic inflammatory demyelinating polyradiculoneuropathy and Paraproteinemic neuropathies (category I, level 1B). Moreover, TPE in
kidney diseases, for instance: desensitization in
renal transplantation(ABO compatible) (living donor)and desensitization in deceased donor, desensitization in
renal transplantation(ABO incompatible) (living donor),
thrombotic microangiopathy complement Mediated (
Factor H autoantibodies),
Focal segmental glomerulosclerosis(recurrent in transplanted kidney),
ANCA-associated rapidly progressive
glomerulonephritis(Dialysis dependence, DAH),
Anti-Glomerular basement membrane disease Goodpasture's syndrome)(DAH,Dialysis-independence,) has been utilized as an initial treatment. (category I) TPE has been used as the key therapeutic modality to reduce anti-A or anti-B antibody titers in the liver peri-transplant period with the goal of preventing rejection and facilitating graft survival. Also,
plasma exchange is the first-line
therapy in
Wilson's disease (category I, level1C).